The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant albumin-bound paclitaxel plus gemcitabine reshapes pancreatic ductal adenocarcinoma stroma by enriching TMEM100+ cancer-associated fibroblasts in nonresponders.
- Why it matters: Secondary resistance to this standard neoadjuvant regimen is common, but the stromal programs that enable it are not well defined.
- What they did: Single-cell transcriptomics of patient tumors assessed CAF state changes after AG therapy, and mechanistic work tested IL-2-STAT5–driven TMEM100 induction by albumin-bound paclitaxel.
- The result: TMEM100+ CAFs promote chemoresistance via paracrine amphiregulin and tumor EGFR signaling, and genetic ablation of TMEM100+ CAFs in mouse models reversed CAF switching and enhanced AG antitumor efficacy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.